1-8 of 8
Himal Amin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Elena Zamagni, Mario Boccadoro, Andrew Spencer, Michel Delforge, Donna E. Reece, Agoston Gyula Szabo, Hermann Einsele, Evangelos Terpos, Fredrik Schjesvold, Jelena Bila, Christoph Driessen, Meral Beksac, Gordon Cook, Cesar Rodriguez, Lixia Pei, Yingqi Shi, Caline Sakabedoyan, Jagaoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels WCJ Van De Donk
Journal: Blood
Blood (2022) 140 (Supplement 1): 7289–7291.
https://doi.org/10.1182/blood-2022-159756
Published: 2022
Journal Articles

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Pieter Sonneveld, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Yanping Qiu, Himal Amin, Michele Kosh, NamPhuong Tran, Robin Carson, Meletios A. Dimopoulos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2747.
https://doi.org/10.1182/blood-2021-146907
Published: 2021
Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD, Mario Boccadoro, Sosana Delimpasi, MD, Meral Beksac, MD, Eirini Katodritou, MD, Philippe Moreau, MD, Luca Baldini, MD PhD, Argiris Symeonidis, MD PhD, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, MD PhD, Hermann Einsele, MD, Ioannis Orfanidis, Tahamtan Ahmadi, MD PhD, Jon Ukropec, PhD, Tobias Kampfenkel, MD, Jordan Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, MD PhD, Robin Carson, MD BA, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-135874
Published: 2020
Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Suzanne Lentzsch, MD PhD, Hang Quach, MD FRACP, FRCPA, MBBS, Marcelo Capra, MD PhD, Roberto Ovilla, MD, Jae-Cheol Jo, MD, Ho-Jin Shin, MD PhD, Pieter Sonneveld, MD PhD, Ming Qi, MD PhD, Himal Amin, Jianping Wang, Xiang Qin, Linda Okonkwo, Jon Ukropec, PhD, Sonali Trivedi, Kenshi Suzuki, MD PhD, Meletios A Dimopoulos, MD, Michele Cavo, MD, Ajay K Nooka, MD MPH, Ajai Chari, MD, Thierry Facon
Journal: Blood
Blood (2018) 132 (Supplement 1): 3288.
https://doi.org/10.1182/blood-2018-99-112669
Published: 2018
Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Maria-Victoria Mateos, MD PhD, Pieter Sonneveld, MD PhD, Vania T. M. Hungria, MD PhD, Ajay K Nooka, MD MPH, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Katja Weisel, MD, Christopher Chiu, PhD, Jordan M. Schecter, Himal Amin, Xiang Qin, Ming Qi, Andrew Spencer, MBBS, FRACP, FRCPA, DM
Journal: Blood
Blood (2018) 132 (Supplement 1): 3270.
https://doi.org/10.1182/blood-2018-99-112554
Published: 2018
Journal Articles

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Suzanne Lentzsch, Hang Quach, MBBS, MD, Asher A. Chanan-Khan, MD, Noemi Horvath, FRACP, Marcelo Capra, MD PhD, Roberto Ovilla, MD, Jae-Cheol Jo, MD, Ho-Jin Shin, MD, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, PhD, Pieter Sonneveld, MDPhD, Jordan Schecter, Vania T M Hungria, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1852.
https://doi.org/10.1182/blood.V130.Suppl_1.1852.1852
Published: 2017
Journal Articles

Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor

Maria-Victoria Mateos, MD PhD, Jane Estell, B.MD(Honours), FRACP, FRCPA, Wolney Barreto, PhD, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Ming Qi, Jordan Schecter, Himal Amin, Xiang Qin, William Deraedt, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Ajay Nooka, MD MPH
Journal: Blood
Blood (2016) 128 (22): 1150.
https://doi.org/10.1182/blood.V128.22.1150.1150
Published: 2016
Journal Articles

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Asher A. Chanan-Khan, MD, Suzanne Lentzsch, MD PhD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, Marcelo Capra, MD PhD, Roberto Ovilla, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3313.
https://doi.org/10.1182/blood.V128.22.3313.3313
Published: 2016